Meeting
2016 ASCO Annual Meeting
Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors.
Authors
Monica Khunger
Cleveland Clinic, Cleveland, OH
Monica Khunger , Sagar Rakshit , Kurt Alex Schalper , Paul Elson , Nathan A. Pennell , James Stevenson , Vamsidhar Velcheti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Tumor-Based Biomarkers
Citation
J Clin Oncol 34, 2016 (suppl; abstr 11603)
DOI
10.1200/JCO.2016.34.15_suppl.11603
Abstract #
11603
Poster Bd #
300
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC).
First Author: Rathi Narayana Pillai
First Author: Jeddeo Paul
Poster
2018 ASCO Annual Meeting
Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC.
First Author: Ferdinandos Skoulidis
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang